Evidence map›Paper›PMID 40746553›Full record

ArticleFrontiers in immunology2025

Hyperglycemia enhances group B

Rodrigo Jiménez-Escutia, Arumi Villafuerte-Pérez, Donovan Vargas-Alcantar, Karina Martínez-Garfias, Samara Rodríguez-Flores, Pilar Velázquez-Sánchez, Amaury Fortanel-Fonseca, Rodrigo Zamora-Escudero, Marcela Islas-López, Ismael Mancilla-Herrera and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Type 2 diabetes mellitus exacerbates vaginal group BbioRxiv : the preprint server for biology · 2026
    Article
  3. Frontiers in medicine · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rodrigo Jiménez-EscutiaDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Arumi Villafuerte-PérezDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Donovan Vargas-AlcantarDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Karina Martínez-GarfiasDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Samara Rodríguez-FloresDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Pilar Velázquez-SánchezDepartamento de Ginecología y Obstetricia, Hospital Ángeles México, Mexico City, Mexico.
Amaury Fortanel-FonsecaDepartamento de Ginecología y Obstetricia, Hospital Ángeles México, Mexico City, Mexico.
Rodrigo Zamora-EscuderoGinecología y Obstetricia, Hospital Ángeles Lomas - Universidad Nacional Autónoma de México (UNAM), Naucalpan, Mexico.
Marcela Islas-LópezGinecología y Obstetricia, Hospital Ángeles Lomas - Universidad Nacional Autónoma de México (UNAM), Naucalpan, Mexico.
Ismael Mancilla-HerreraSubdirección de Investigación Biomédica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Lorenza DíazDepartamento de Biología de la Reproducción, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Verónica Zaga-ClavellinaDirección de Investigación, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.
Andrea Olmos-OrtizDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Elevated glucose levels during pregnancy disrupt placental structure, signaling, and cellular interactions, impairing its immune response. In mothers with gestational diabetes mellitus (GDM), Methods: Human villous explants from term, normoevolutive pregnancies were cultured with 5, 10 or 50 mM glucose, and subsequently infected or not with GBS. Bacterial growth and adherence to villous tissue, syncytial disruption, cytokine and chemokine mRNA expression and secretion, leukocyte chemotaxis using intervillous blood mononuclear cells (IVMC), and TLR-2 expression at both mRNA and protein levels, were evaluated. Results: Under high glucose conditions, GBS showed increased proliferation and invasiveness, while villous explants presented evidence of syncytial barrier degradation. Also, placental TNF-α, MCP-1, and MIP-1β were induced by GBS infection. However, the dual challenge of high glucose and infection reduced the above inflammatory markers' gene and protein synthesis. GBS infection enhanced IVMC migration compared to uninfected groups, but the combination of GBS and hyperglycemia led to a reduced migration of IVMC, particularly monocytes and NK cells. TLR-2 placental expression was also downregulated by this dual challenge. Conclusion: At the placental level, hyperglycemia attenuates the immune response against GBS infection, promoting syncytial disruption, bacterial growth, and tissue colonization. The combined stimulus of hyperglycemia and GBS resulted in reduced placental expression of TLR-2, TNF-α, MCP-1, and MIP-1β, thereby impairing the chemotaxis of IVMC, monocytes, and NK cells. This dysregulated immune response may compromise bacterial clearance and placental integrity, favoring pathogen persistence. Our findings suggest a potential mechanism by which hyperglycemia increases susceptibility to GBS-associated complications, offering novel insight into the interplay between metabolic and infectious stressors at the maternal-fetal interface.

Indexed as

HyperglycemiaPlacentaPregnancy Complications, InfectiousStreptococcal InfectionsStreptococcus agalactiaeToll-Like Receptor 2ChemotaxisCytokinesDiabetes, GestationalFemaleGlucoseHumansPregnancyCytokinesGlucoseTLR2 protein, humanToll-Like Receptor 2gestational diabetes mellitusglucoseMCP-1MIP-1 betamonocytesNK cellsStreptococcus agalactiaeTLR-2

Identifiers

PMID40746553
PMCPMC12310592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.